NasdaqGS:SDGR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. More Details


Snowflake Analysis

Flawless balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Schrödinger's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SDGR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: SDGR's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

2.2%

SDGR

0.09%

US Healthcare Services

-1.0%

US Market


1 Year Return

n/a

SDGR

62.1%

US Healthcare Services

19.6%

US Market

Return vs Industry: Insufficient data to determine how SDGR performed against the US Healthcare Services industry.

Return vs Market: Insufficient data to determine how SDGR performed against the US Market.


Shareholder returns

SDGRIndustryMarket
7 Day2.2%0.09%-1.0%
30 Day16.0%4.4%2.2%
90 Day56.9%3.0%11.5%
1 Yearn/a62.6%62.1%22.3%19.6%
3 Yearn/a150.6%148.5%45.3%35.7%
5 Yearn/a241.0%237.0%124.8%99.8%

Long-Term Price Volatility Vs. Market

How volatile is Schrödinger's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Schrödinger undervalued compared to its fair value and its price relative to the market?

10.01x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SDGR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SDGR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SDGR is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.

PE vs Market: SDGR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SDGR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SDGR is overvalued based on its PB Ratio (10x) compared to the US Healthcare Services industry average (6.4x).


Next Steps

Future Growth

How is Schrödinger forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

57.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SDGR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: SDGR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SDGR's is expected to become profitable in the next 3 years.

Revenue vs Market: SDGR's revenue (29.9% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: SDGR's revenue (29.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SDGR's Return on Equity is forecast to be low in 3 years time (6.9%).


Next Steps

Past Performance

How has Schrödinger performed over the past 5 years?

16.9%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: SDGR is currently unprofitable.

Growing Profit Margin: SDGR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if SDGR's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare SDGR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SDGR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-29.9%).


Return on Equity

High ROE: SDGR has a negative Return on Equity (-3.52%), as it is currently unprofitable.


Next Steps

Financial Health

How is Schrödinger's financial position?


Financial Position Analysis

Short Term Liabilities: SDGR's short term assets ($621.1M) exceed its short term liabilities ($39.3M).

Long Term Liabilities: SDGR's short term assets ($621.1M) exceed its long term liabilities ($10.0M).


Debt to Equity History and Analysis

Debt Level: SDGR is debt free.

Reducing Debt: SDGR has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SDGR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: SDGR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 18.9% each year


Next Steps

Dividend

What is Schrödinger current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SDGR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SDGR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SDGR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SDGR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SDGR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Ramy Farid (56 yo)

4yrs

Tenure

US$633,101

Compensation

Dr. Ramy Farid, Ph.D., serves as the President of Schrödinger, LLC since January 2008 and has been its Chief Executive Officer since January 2, 2017. Dr. Farid served as Director of Morphic Holding, Inc. f...


CEO Compensation Analysis

Compensation vs Market: Ramy's total compensation ($USD633.10K) is below average for companies of similar size in the US market ($USD6.20M).

Compensation vs Earnings: Ramy's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ramy Farid
CEO, President & Director4yrsUS$633.10k0.27%
$ 16.8m
Richard Friesner
Co-Founder4.5yrsUS$347.00k1.96%
$ 123.6m
Yvonne Tran
Executive VP11yrsUS$547.62k0.039%
$ 2.5m
Cony D'Cruz
Executive VP & Chief Business Officer5yrsUS$587.60k0.23%
$ 14.8m
William Goddard
Co-Founder & Scientific Advisorno datano datano data
Joel Lebowitz
CFO & Executive VP2.17yrsUS$940.95kno data
Kenneth Lorton
Senior VP & CTO3.75yrsno data0.069%
$ 4.4m
Robert Abel
Executive Vice President of Science1yrno data0%
$ 0
Shane Brauner
Senior VP & Chief Information Officer4yrsno data0.036%
$ 2.3m
Jaren Madden
Senior VP of Investor Relations & Corporate Communications1yrno datano data
Jennifer Daniel
Senior VP & Chief Human Resources Officer3.92yrsno data0.0096%
$ 607.6k
Michelle Byington
Vice President of Human Resourcesno datano datano data

4.0yrs

Average Tenure

51yo

Average Age

Experienced Management: SDGR's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ramy Farid
CEO, President & Director4yrsUS$633.10k0.27%
$ 16.8m
Richard Friesner
Co-Founder4.5yrsUS$347.00k1.96%
$ 123.6m
William Goddard
Co-Founder & Scientific Advisorno datano datano data
Michael Lynton
Independent Chairman of the Board2.25yrsno data0%
$ 0
Timothy Wright
Independent Directorno datano datano data
Gary Ginsberg
Independent Director0.67yrno datano data
Gary Sender
Independent Director1.5yrsUS$130.37k0%
$ 0
Rosana Kapeller-Libermann
Independent Director2yrsUS$130.23k0%
$ 0
Brian Shoichet
Scientific Advisorno datano datano data
Nancy Thornberry
Independent Director1.33yrsUS$307.59kno data
Jeffrey Chodakewitz
Independent Director0.67yrno datano data
Adrian Roitberg
Scientific Advisorno datano datano data

1.8yrs

Average Tenure

60yo

Average Age

Experienced Board: SDGR's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SDGR insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: SDGR only recently listed within the past 12 months.


Top Shareholders

Company Information

Schrödinger, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Schrödinger, Inc.
  • Ticker: SDGR
  • Exchange: NasdaqGS
  • Founded: 1990
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$6.316b
  • Shares outstanding: 69.49m
  • Website: https://www.schrodinger.com

Number of Employees


Location

  • Schrödinger, Inc.
  • 120 West 45th Street
  • 17th Floor
  • New York
  • New York
  • 10036
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SDGRNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2020

Biography

Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldw...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/17 00:48
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.